Publicaciones en las que colabora con Eduardo Carlos Salido Ruiz (74)

2024

  1. Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast-like synoviocytes by liver X receptors

    European Journal of Immunology, Vol. 54, Núm. 11

  2. Postcolonoscopy colorectal cancer: Prevalence, categorization and root-cause analysis based on the World Endoscopic Organization system

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 319-326

2023

  1. Beta human papillomavirus as a facilitator in the initial phase but not a perpetuator of skin carcinogenesis

    JEADV Clinical Practice

2022

  1. Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

    BMC Nephrology, Vol. 23, Núm. 1

2021

  1. Hiperoxalurias. Oxalosis

    Nefrología pediátrica (Ediciones de la Universidad de Oviedo), pp. 1011-1020

2020

  1. The Iberian pig fed with high-fat diet: a model of renal disease in obesity and metabolic syndrome

    International Journal of Obesity, Vol. 44, Núm. 2, pp. 457-465

2019

  1. Comprehensive clinical, molecular and histopathological analysis of bone marrow in chronic myeloproliferative neoplasia

    Revista Clinica Espanola, Vol. 219, Núm. 8, pp. 440-444

2018

  1. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

    Kidney International Reports, Vol. 3, Núm. 6, pp. 1304-1315

  2. Renal disease in obesity, metabolic syndrome and diabesity

    Diabetic Nephropathy: Pathophysiology and Clinical Aspects (Springer International Publishing), pp. 65-80

2017

  1. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells

    American Journal of Transplantation, Vol. 17, Núm. 11, pp. 2829-2840

  2. Does the mutational status affect the bone marrow morphological findings in patients with classical Philadelphia-negative myeloproliferative neoplasms?

    Journal of Hematopathology

  3. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant

    Drug Metabolism and Personalized Therapy, Vol. 32, Núm. 1, pp. 49-58

  4. Molecular therapy of primary hyperoxaluria

    Journal of Inherited Metabolic Disease, Vol. 40, Núm. 4, pp. 481-489

  5. Vascular Damage and Kidney Transplant Outcomes: An Unfriendly and Harmful Link

    American Journal of the Medical Sciences, Vol. 354, Núm. 1, pp. 7-16

2016

  1. Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease

    PLoS ONE, Vol. 11, Núm. 5

  2. Iohexol plasma clearance, a simple and reliable method to measure renal function in conscious mice

    Pflugers Archiv European Journal of Physiology, Vol. 468, Núm. 9, pp. 1587-1594

  3. Metaloproteinasa 9 como biomarcador plasmático de neoplasia colorrectal avanzada

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 7, pp. 433-441

2015

  1. Artery wall assessment helps predict kidney transplant outcome

    PLoS ONE, Vol. 10, Núm. 6

  2. Clinicopathological analysis of factors related to colorectal tumor perforation

    Medicine (United States), Vol. 94, Núm. 15

  3. Estimated glomerular filtration rate in renal transplantation: The nephrologist in the mist

    Transplantation, Vol. 99, Núm. 12, pp. 2625-2633